Emily Drabant Conley, Ph.D., is Director of Business Development at 23andMe, a Silicon Valley-based biotech company. 23andMe provides individuals with direct access to their genetic information and offers researchers a platform to accelerate clinical development and conduct patient-centric studies. She is responsible for leading business development efforts and building strategic relationships with pharmaceutical and biotech partners, forging research collaborations, and overseeing project execution across a range of therapeutic areas. Dr. Conley joined 23andMe in 2010 out of a desire to accelerate the pace of clinical research and personalized medicine. Prior to this role she spent 10 years conducting research that combined genetics and neuroimaging techniques to identify biological pathways that impact risk for neuropsychiatric disease. She received her Ph.D. in Neuroscience from Stanford University School of Medicine, where she held fellowships from the National Science Foundation and Department of Defense. Prior to that, she was a Research Fellow at the National Institute of Mental Health. She graduated Summa Cum Laude from Vanderbilt University with a B.A. with High Honors in Psychology and Business. Dr. Conley currently serves on the Advisory Board of the UCSF Alliance Health Project, which provides services to the LGBT and HIV-affected communities in San Francisco. She is a co-author on over 15 academic publications and was has been interviewed by NPR, FOX, ABC, and Fast Company among others.